Get the Stockscreener App
4.25
0.71%
0.03
Sight Sciences Inc stock is traded at $4.25, with a volume of 67,027.
It is up +0.71% in the last 24 hours and up +32.81% over the past month.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
See More
Previous Close:
$4.22
Open:
$4.26
24h Volume:
67,027
Relative Volume:
0.38
Market Cap:
$215.60M
Revenue:
$81.06M
Net Income/Loss:
$-55.55M
P/E Ratio:
-3.7281
EPS:
-1.14
Net Cash Flow:
$-47.98M
1W Performance:
-0.47%
1M Performance:
+32.81%
6M Performance:
+17.73%
1Y Performance:
-32.75%
1-Day Range:
$4.19
$4.28
1-Week Range:
$4.018
$4.456
52-Week Range:
$2.03
$8.45
Sight Sciences Inc Stock (SGHT) Company Profile
Name
Sight Sciences Inc
Sector
Industry
Phone
(415) 889-0550
Address
4040 CAMPBELL AVE,, MENLO PARK
Compare SGHT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SGHT
Sight Sciences Inc
|
4.25 | 215.60M | 81.06M | -55.55M | -47.98M | -1.14 |
|
ABT
Abbott Laboratories
|
133.67 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.58 | 147.06B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
390.40 | 145.64B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
86.18 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.15 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Sight Sciences Inc Stock (SGHT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | UBS | Buy |
| Nov-04-24 | Downgrade | Lake Street | Buy → Hold |
| Aug-21-24 | Initiated | Lake Street | Buy |
| Sep-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-12-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-24-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-10-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-06-23 | Upgrade | Stifel | Hold → Buy |
| Oct-04-22 | Initiated | Needham | Hold |
| Jul-26-22 | Initiated | Stifel | Hold |
| Feb-03-22 | Initiated | William Blair | Outperform |
| Jan-07-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Sight Sciences Inc Stock (SGHT) Latest News
Sight Sciences (SGHT) Price Target Raised by Piper Sandler | SGHT Stock News - GuruFocus
Piper Sandler raises Sight Sciences price target to $4 on technology outlook - Investing.com India
Sight Sciences (SGHT) Sees Price Target Increase Amid Market Recovery | SGHT Stock News - GuruFocus
Sight Sciences price target raised to $4 from $3.50 at Piper Sandler - TipRanks
Sight Sciences Uses RWE To Refine Patient Segmentation And Reverse A Medicare Ruling For OMNI - Clinical Leader
Millennium Management LLC Invests $464,000 in Sight Sciences, Inc. (NASDAQ:SGHT) - Defense World
Sight Sciences director Encrantz buys $381,957 in common stock By Investing.com - Investing.com Nigeria
Sight Sciences director Encrantz buys $381,957 in common stock - Investing.com Australia
sight sciences appoints new board member and holds annual meeting By Investing.com - Investing.com South Africa
sight sciences appoints new board member and holds annual meeting - Investing.com India
Sight Sciences Holds Annual Stockholders Meeting - TipRanks
ProShare Advisors LLC Makes New $36,000 Investment in Sight Sciences, Inc. (NASDAQ:SGHT) - Defense World
Sight sciences director Encrantz buys $376,429 in stock By Investing.com - Investing.com Nigeria
Sight sciences director Encrantz buys $376,429 in stock - Investing.com Australia
Sight Sciences Independent Chairman Acquires 7.8% More Stock - simplywall.st
Sight Sciences, Inc. (NASDAQ:SGHT) Receives Consensus Rating of “Hold” from Analysts - Defense World
Sight sciences director Staffan Encrantz buys $451k in stock By Investing.com - Investing.com UK
Sight sciences director Staffan Encrantz buys $451k in stock - Investing.com Australia
BNP Paribas Financial Markets Invests $262,000 in Sight Sciences, Inc. (NASDAQ:SGHT) - Defense World
Sight Sciences, Inc. (NASDAQ:SGHT) Shares Sold by Bank of America Corp DE - Defense World
Northern Trust Corp Has $1.21 Million Stock Holdings in Sight Sciences, Inc. (NASDAQ:SGHT) - Defense World
Sight Sciences at Stifel Forum: Strategic Growth Amid Challenges By Investing.com - Investing.com Canada
Sight Sciences price target raised to $3.60 from $3.20 at Citi - TipRanks
D. E. Shaw & Co. Inc. Acquires 88,738 Shares of Sight Sciences, Inc. (NASDAQ:SGHT) - Defense World
Sight Sciences (SGHT) Receives Increased Price Target from Citigroup | SGHT Stock News - GuruFocus
Sight Sciences (SGHT) Receives Increased Price Target from Citig - GuruFocus
Sight Sciences (SGHT) Target Price Raised by Citi | SGHT Stock News - GuruFocus
Sight Sciences, Inc. (NASDAQ:SGHT) Shares Purchased by Dimensional Fund Advisors LP - Defense World
Nautilus Biotechnology And 2 Other Penny Stocks With Promising Potential - simplywall.st
Sight Sciences to Present at the Stifel 2025 Virtual Ophthalmology Forum on May 27th - The Manila Times
Sight Sciences Reveals New Ophthalmology Tech Updates at Exclusive Stifel 2025 ForumLive Webcast Available - Stock Titan
Sight Sciences, Inc. (NASDAQ:SGHT) Surges 44% Yet Its Low P/S Is No Reason For Excitement - simplywall.st
Sight Sciences, Inc. (NASDAQ:SGHT) Shares Acquired by Wells Fargo & Company MN - Defense World
Sight Sciences, Inc. (NASDAQ:SGHT) Shares Purchased by Barclays PLC - Defense World
Sight Sciences (NASDAQ:SGHT) Price Target Raised to $3.00 - Defense World
Sight Sciences, Inc. (NASDAQ:SGHT) Q1 2025 Earnings Call Transcript - MSN
Analysts Have Conflicting Sentiments on These Healthcare Companies: Evolent Health (EVH), Verastem (VSTM) and Sight Sciences (SGHT) - The Globe and Mail
Sight Sciences (SGHT) Price Target Raised Amid Growth Potential - GuruFocus
Sight Sciences (SGHT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - MSN
Sight Sciences, Inc. Earnings Call: Mixed Results and Strategic Focus - TipRanks
Earnings call transcript: Sight Sciences misses Q1 2025 EPS forecast, stock rises - Investing.com Nigeria
Sight Sciences stock holds as Needham reiterates rating By Investing.com - Investing.com Nigeria
Sight Sciences stock holds as Needham reiterates rating - Investing.com
Sight Sciences: Balancing Resilience and Caution Amid Tariff Challenges - TipRanks
Sight Sciences (SGHT): Analyst Raises Price Target Despite Hold Rating | SGHT Stock News - GuruFocus
Sight Sciences Inc (SGHT) Q1 2025 Earnings Call Highlights: Navigating Market Challenges and ... By GuruFocus - Investing.com Canada
Sight Sciences Inc Stock (SGHT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Sight Sciences Inc Stock (SGHT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Encrantz Staffan | Director |
Jun 06 '25 |
Buy |
4.22 |
27,900 |
117,738 |
1,377,964 |
| Encrantz Staffan | Director |
Jun 04 '25 |
Buy |
4.17 |
21,674 |
90,424 |
1,278,161 |
| Encrantz Staffan | Director |
May 30 '25 |
Buy |
3.67 |
42,753 |
156,904 |
1,200,458 |
| Encrantz Staffan | Director |
Jun 02 '25 |
Buy |
3.88 |
30,799 |
119,439 |
1,231,257 |
| Encrantz Staffan | Director |
Jun 03 '25 |
Buy |
3.97 |
25,230 |
100,087 |
1,256,487 |
| Encrantz Staffan | Director |
May 29 '25 |
Buy |
3.59 |
60,128 |
215,739 |
1,157,705 |
| Encrantz Staffan | Director |
May 27 '25 |
Buy |
3.44 |
41,346 |
142,065 |
1,070,862 |
| Encrantz Staffan | Director |
May 28 '25 |
Buy |
3.52 |
26,715 |
93,930 |
1,097,577 |
| Bauerlein Alison | Chief Financial Officer |
May 19 '25 |
Sale |
3.48 |
13,066 |
45,430 |
636,728 |
1.18%
0.77%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):